U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Reuters · 12/18/2025 12:00

Please log in to view news